利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.022 秒)

    Compositions for treating respiratory viral infections and their use
    3.
    发明授权
    Compositions for treating respiratory viral infections and their use 有权
    用于治疗呼吸道病毒感染及其用途的组合物

    公开(公告)号：US08691781B2

    公开(公告)日：2014-04-08

    申请号：US11792179

    申请日：2005-11-04

    申请人： Qingquan Tang ,  Patrick Lu ,  Martin Woodle ,  Bojian Zheng

    发明人： Qingquan Tang ,  Patrick Lu ,  Martin Woodle ,  Bojian Zheng

    IPC分类号： A01N43/04 ,  C12Q1/68 ,  C12N15/58 ,  C07H21/02 ,  C07H21/04

    CPC分类号： A61K31/711 ,  A61K31/7105 ,  C12N15/1131 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/53 ,  C12N2760/16111 ,  C12N2760/18511

    摘要： The invention provides siRNA compositions that interfere with viral replication in respiratory viral infections, including respiratory syncytial virus and avian influenza A, including the H5N1 strain. The invention further provides uses of the siRNA compositions to inhibit expression of viral genes in respiratory virus-infected cells, and to uses in the treatment of respiratory virus infections in a subject. Generally the invention provides polynucleotide that includes a first nucleotide sequence of 15 to 30 bases that targets the genome of a respiratory syncytial virus or an influenza A virus, a complement thereof, a double stranded polynucleotide or a hairpin polynucleotide. Additionally the invention provides vectors, cells and pharmaceutical compositions containing siRNA sequences.

    摘要翻译： 本发明提供干扰呼吸道病毒感染（包括呼吸道合胞病毒和禽流感A）包括H5N1毒株在内的病毒复制的siRNA组合物。 本发明还提供siRNA组合物用于抑制呼吸道病毒感染细胞中病毒基因表达的用途，以及用于治疗受试者中的呼吸道病毒感染的用途。 本发明通常提供多核苷酸，其包含15至30个碱基的第一核苷酸序列，其靶向呼吸道合胞病毒或甲型流感病毒的基因组，其补体，双链多核苷酸或发夹多核苷酸。 另外，本发明提供了含有siRNA序列的载体，细胞和药物组合物。

    SiRNA compositions and methods for potently inhibiting viral infection
    4.
    发明授权
    SiRNA compositions and methods for potently inhibiting viral infection 有权
    SiRNA组合物和有效抑制病毒感染的方法

    公开(公告)号：US08828962B2

    公开(公告)日：2014-09-09

    申请号：US13323364

    申请日：2011-12-12

    申请人： Bojian Zheng ,  Hongyan Sui ,  Yongping Lin

    发明人： Bojian Zheng ,  Hongyan Sui ,  Yongping Lin

    IPC分类号： A61K31/70 ,  C07H21/02 ,  C07H21/04 ,  A61K31/713 ,  A61K31/7105 ,  C12N15/11 ,  C12N15/113 ,  C12Q1/68

    CPC分类号： A61K31/713 ,  A61K31/7105 ,  C12N15/111 ,  C12N15/113 ,  C12N15/1131 ,  C12N2310/14 ,  C12N2320/10

    摘要： No antiviral regimen has been consistently successful in treating H5N1 virus infection. We demonstrate that a group of highly effective siRNAs targeting different H5N1 viral genes shares a unique motif, GGAGU/ACUCC. We further demonstrate that the effectiveness of siRNAs containing this motif is not sequence specific. The results suggested that the structure of the unique motif is critical in determining the potency of siRNA-mediated protective effects against viral infection and this potent in vivo protection is associated with early productions of β-defensin and IL-6 induced by the motif. Provided are methods and prophylactic and therapeutic agents useful against other viral infections in addition to the H5N1 influenza virus.

    摘要翻译： 没有抗病毒方案一直在治疗H5N1病毒感染成功。 我们证明一组针对不同H5N1病毒基因的高效siRNA共享独特的基序GGAGU / ACUCC。 我们进一步证明含有该基序的siRNA的有效性不是序列特异性的。 结果表明，独特基序的结构对于确定siRNA介导的针对病毒感染的保护作用的效力至关重要，并且这种有效的体内保护与由该基序诱导的早期产生的 - 防御素和IL-6相关。 提供了除了H5N1流感病毒之外还可用于其它病毒感染的方法和预防和治疗剂。

    siRNA compositions and methods for potently inhibiting viral infection
    5.
    发明授权
    siRNA compositions and methods for potently inhibiting viral infection 有权
    siRNA组合物和有效抑制病毒感染的方法

    公开(公告)号：US08664188B2

    公开(公告)日：2014-03-04

    申请号：US12636234

    申请日：2009-12-11

    申请人： Bojian Zheng ,  Hongyan Sui ,  Yongping Lin

    发明人： Bojian Zheng ,  Hongyan Sui ,  Yongping Lin

    IPC分类号： A61K31/70 ,  C07H21/02 ,  C07H21/04 ,  C12Q1/68

    CPC分类号： A61K31/713 ,  A61K31/7105 ,  C12N15/111 ,  C12N15/113 ,  C12N15/1131 ,  C12N2310/14 ,  C12N2320/10

    摘要： No antiviral regimen has been consistently successful in treating H5N1 virus infection. We demonstrate that a group of highly effective siRNAs targeting different H5N1 viral genes shares a unique motif, GGAGU/ACUCC. We further demonstrate that the effectiveness of siRNAs containing this motif is not sequence specific. The results suggested that the structure of the unique motif is critical in determining the potency of siRNA-mediated protective effects against viral infection and this potent in vivo protection is associated with early productions of β-defensin and IL-6 induced by the motif. Provided are methods and prophylactic and therapeutic agents useful against other viral infections in addition to the H5N1 influenza virus.

    摘要翻译： 没有抗病毒方案一直在治疗H5N1病毒感染成功。 我们证明一组针对不同H5N1病毒基因的高效siRNA共享独特的基序GGAGU / ACUCC。 我们进一步证明含有该基序的siRNA的有效性不是序列特异性的。 结果表明，独特基序的结构对于确定siRNA介导的针对病毒感染的保护作用的效力至关重要，并且这种有效的体内保护与由该基序诱导的β-防御素和IL-6的早期产生相关。 提供了除了H5N1流感病毒之外还可用于其它病毒感染的方法和预防和治疗剂。

    COMBINATION THERAPY FOR THE TREATMENT OF INFLUENZA
    6.
    发明申请
    COMBINATION THERAPY FOR THE TREATMENT OF INFLUENZA 审中-公开
    用于治疗流感的组合治疗

    公开(公告)号：US20090298797A1

    公开(公告)日：2009-12-03

    申请号：US12469319

    申请日：2009-05-20

    申请人： Bojian Zheng ,  Kowk-Yung Yuen

    发明人： Bojian Zheng ,  Kowk-Yung Yuen

    IPC分类号： A61K31/60 ,  A61K31/415 ,  A61K31/35 ,  A61P31/16

    CPC分类号： A61K45/06 ,  A61K31/155 ,  A61K31/196 ,  A61K31/415 ,  A61K31/606 ,  A61K2300/00

    摘要： Compositions and methods for treating one or more symptoms of influenza, preferably influenza due to infection with influenza A (H5N1) are provided. It has been discovered that administration of a combination of a neuraminidase inhibitor with two immunomodulators increases survivability in subjects 24, 48, or even 72 hours post infection compared to administration of the neuraminidase inhibitor alone. A preferred neuraminidase inhibitor is zanamivir. Preferred immunomodulators include, but are not limited to celecoxib and mesalazine. Another embodiment provides a method for treating influenza, preferably, influenza due to infection with avian influenza A (H5N1) by administering to subject infected with the influenza virus, an effective amount of a neuraminidase inhibitor to inhibit or reduce budding of the influenza virus from infected cells of the subject, and an effective amount of at least two immunomodulators effective to reduce or inhibit one or more symptoms of inflammation in the subject.

    摘要翻译： 提供用于治疗一种或多种流行性感冒症状的组合物和方法，优选因感染甲型流感（H5N1）感染流感。 已经发现，与单独施用神经氨酸酶抑制剂相比，神经氨酸酶抑制剂与两种免疫调节剂的组合的施用增加了感染后24,48或甚至72小时的受试者的存活率。 优选的神经氨酸酶抑制剂是扎那米韦。 优选的免疫调节剂包括但不限于塞来昔布和美沙拉嗪。 另一个实施方案提供了一种治疗流行性感冒的方法，优选地，由于禽流感A（H5N1）的感染，通过对感染了流感病毒的受试者施用有效量的神经氨酸酶抑制剂来抑制或减少感染的流感病毒的出芽 受试者的细胞和有效量的至少两种有效减少或抑制受试者中一种或多种炎症症状的免疫调节剂。

    Compositions For Treating Respiratory Viral Infections and Their Use
    7.
    发明申请
    Compositions For Treating Respiratory Viral Infections and Their Use 有权
    用于治疗呼吸道病毒感染及其使用的组合物

    公开(公告)号：US20080279920A1

    公开(公告)日：2008-11-13

    申请号：US11792179

    申请日：2005-11-04

    申请人： Qingquan Tang ,  Patrick Y. Lu ,  Frank Y. Xie ,  Martin C. Woodle ,  Bojian Zheng

    发明人： Qingquan Tang ,  Patrick Y. Lu ,  Frank Y. Xie ,  Martin C. Woodle ,  Bojian Zheng

    IPC分类号： A61K31/7105 ,  A61K31/711 ,  C12N15/31 ,  C12N15/85 ,  C12N5/10 ,  A61K9/127 ,  A61P31/16

    CPC分类号： A61K31/711 ,  A61K31/7105 ,  C12N15/1131 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/53 ,  C12N2760/16111 ,  C12N2760/18511

    摘要： The invention provides siRNA compositions that interfere with viral replication in respiratory viral infections, including respiratory syncytial virus and avian influenza A, including the H5N1 strain. The invention further provides uses of the siRNA compositions to inhibit expression of viral genes in respiratory virus-infected cells, and to uses in the treatment of respiratory virus infections in a subject. Generally the invention provides polynucleotide that includes a first nucleotide sequence of 15 to 30 bases that targets the genome of a respiratory syncytial virus or an influenza A virus, a complement thereof, a double stranded polynucleotide or a hairpin polynucleotide. Additionally the invention provides vectors, cells and pharmaceutical compositions containing siRNA sequences.

    摘要翻译： 本发明提供干扰呼吸道病毒感染（包括呼吸道合胞病毒和禽流感A）包括H5N1毒株在内的病毒复制的siRNA组合物。 本发明还提供siRNA组合物用于抑制呼吸道病毒感染细胞中病毒基因表达的用途，以及用于治疗受试者中的呼吸道病毒感染的用途。 本发明通常提供多核苷酸，其包含15至30个碱基的第一核苷酸序列，其靶向呼吸道合胞病毒或甲型流感病毒的基因组，其补体，双链多核苷酸或发夹多核苷酸。 另外，本发明提供了含有siRNA序列的载体，细胞和药物组合物。